FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
Tommy Douglas Conference Center
10000 New Hampshire Avenue, Silver Spring, Maryland 20903
September 14, 2016

MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Lauren D. Tesh, PharmD, BCPS
Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA
Silver Spring, Maryland

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Bernard F. Cole, PhD
Professor
Department of Mathematics and Statistics
University of Vermont
Burlington, Vermont

Grzegorz S. Nowakowski, MD
Assistant Professor of Medicine
Mayo Clinic Rochester
Rochester, Minnesota

Vassiliki Papadimitrakopoulou, MD
Professor of Medicine
Thoracic/Head and Neck Medical Oncology
MD Anderson Cancer Center
Houston, Texas

Gregory J. Riely, MD, PhD
Associate Attending
Memorial Sloan Kettering Cancer Center
Associate Professor, Weill Cornell Medical College
New York, New York

Brian I. Rini, MD, FACP
Professor of Medicine
Cleveland Clinic Taussig Cancer Institute
Glickman Urological and Kidney Institute
Cleveland, Ohio

Bruce J. Roth, MD
(Chairperson)
Professor of Medicine
Division of Oncology
Washington University School of Medicine
St. Louis, Missouri

Thomas S. Uldrick, MD, MS
Clinical Director
HIV & AIDS Malignancy Branch, Center for Cancer Research
National Cancer Institute
Bethesda, Maryland
Phuong Khanh (P.K.) Morrow, MD, FACP  
(Industry Representative)  
Executive Medical Director, Amgen Oncology  
Therapeutic Area Head, US Medical Organization  
Thousand Oaks, California  

TEMPORARY MEMBERS (Voting)  

Karim Chamie, MD, MSHS  
Assistant Professor of Urology  
Department of Urology  
University of California, Los Angeles  
Los Angeles, California  

Mark L. Gonzalgo, MD, PhD  
Professor  
Department of Urology  
University of Miami Miller School of Medicine  
Miami, Florida  

Pamela J. Haylock, PhD, RN  
(Acting Consumer Representative)  
Adjunct Faculty, Sul Ross State University  
Alpine, Texas  
Oncology Nursing Educator  
Medina, Texas  

Brent Logan, PhD  
Professor and Director  
Division of Biostatistics  
Medical College of Wisconsin  
Milwaukee, Wisconsin  

Patricia A. Spears  
(Patient Representative)  
Raleigh, North Carolina  

Jennifer M. Taylor, MD, MPH  
Assistant Professor, Urology  
Baylor College of Medicine  
Michael E. DeBakey VA Medical Center  
Houston, Texas  

John A. Taylor, III, MD, MS  
Professor of Urology  
Co-Director, Drug Development Discovery & Experimental Therapeutics  
University of Kansas Medical Center  
Kansas City, Kansas
# FDA PARTICIPANTS (Non-Voting)

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Pazdur, MD</td>
<td>Acting Director, Oncology Center of Excellence (OCE), FDA Director, Office of Hematology and Oncology Products (OHOP) Office of New Drugs (OND), CDER, FDA</td>
</tr>
<tr>
<td>Geoffrey Kim, MD</td>
<td>Director Division of Oncology Products 1 (DOP1) OHOP, OND, CDER, FDA</td>
</tr>
<tr>
<td>Ellen Maher, MD</td>
<td>Medical Team Leader Genitourinary Cancers Team DOP1, OHOP, OND, CDER, FDA</td>
</tr>
<tr>
<td>Gwynn Ison, MD</td>
<td>Medical Officer DOP1, OHOP, OND, CDER, FDA</td>
</tr>
<tr>
<td>Chana Weinstock, MD</td>
<td>Medical Officer Genitourinary Cancers Team DOP1, OHOP, OND, CDER, FDA</td>
</tr>
<tr>
<td>Erik Bloomquist, PhD</td>
<td>Statistical Reviewer Division of Biometrics V (DBV) Office of Biometrics (OB) Office of Translational Sciences (OTS) CDER, FDA</td>
</tr>
</tbody>
</table>